Upgrade to remove ads
Top 20 Drugs Week 10 (Black Box Warnings)
Terms in this set (8)
Only physicians experienced in immunosuppression therapy & management of organ transplantation pts. should prescribe this. Pts. should be managed in facilities equipped & staffed with adequate laboratory and supportive medical resources.
Do not administer to pts. who have baseline neutrophil counts of less than 1,500 cells/mm^3.
Not suitable for direct inj.; must be further diluted in sterile 5% dextrose inj. before infusion. Can cause precipitous decreases in blood pressure. May give rise to toxic & potentially lethal levels of cyanide ion. Infusion at maximum dose should never last >10min.
Intended for use only in pts. with the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity (e.g. pulmonary toxicity).
Risk of cardiac arrest from hyperkalemic rhabdomyolysis.
This drug should be administered by adequately trained individuals familiar with its actions, characteristics, & hazards.
Should be administered under supervision of qualified physician experienced in use of cancer chemotherapeutic agents. Bone marrow suppression, notably thrombocytopenia & leukopenia, which may contribute to overwhelming infections in already compromised pt. is most common toxic effect. Hemolytic Uremic Syndrome has been reported.
Epidural or spinal hematomas may occur in pts. who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids & are receiving neuraxial anesthesia or undergoing spinal puncture. May result in long-term or permanent paralysis.
YOU MIGHT ALSO LIKE...
EAQ Medication Questions/Info
CVICU required drugs
pharm and parental therapy EAQ
OTHER SETS BY THIS CREATOR
Top 20 Drugs Week 11 generic
Krebs Part One
Glycolysis Phase Two
Glycolysis Phase One